XENENGMHealthcare·Biotechnology#47 in industry

Xenon Pharmaceuticals Inc.

Reports in 14d· 2026-05-11

+28.0% · 90d

$54.26

-0.98 (-1.77%)

After-Hours $54.26(+0.00)

News

(2)

April 2026

Apr 22, 20265 days agoARSHealthcare

Xene: Summary Unavailable Because Filing Content Is Missing

XENEXenon Pharmaceuticals Inc.

I have reviewed your request and the provided document wrapper. The input only contains the metadata for an SEC filing (Xenon Pharmaceuticals Inc., Form ARS, file name `xene-2026-ars.pdf`), but the actual text, financial data, tables, or content of the filing (the `<PDF>` section) is empty. To pro

Read summaryView on SEC EDGAR

Apr 22, 20265 days agoDEF 14AHealthcare

Xenon Pharmaceuticals proposes annual votes on leadership and executive pay

XENEXenon Pharmaceuticals Inc.

# 📑 What This Document Is This document is a **Proxy Statement (DEF 14A)**. Think of it as the official playbook for Xenon Pharmaceuticals' annual shareholder meeting. Since Xenon is a public company, the board must give shareholders a comprehensive guide detailing everything that will be voted upo

Read summaryView on SEC EDGAR

Key Data

Market Cap$5.24B

Open$55.03

Prev Close$55.24

Day Range$54.02 – $56.11

52W Range$28.19 – $63.95

Volume678,228

P/E (TTM)—

EPS$-4.36

Dividend Yield—

Beta0.74

Price Target$79.24(+46.0%)

Next Earnings2026-05-11(14d)

Analyst Ratings

Strong Buy20 analysts

Buy 20Hold 0Sell 0

About

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Healthcare · Biotechnology

358 employees

www.xenon-pharma.com